{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:13:08Z","timestamp":1791313988261,"version":"4.3.1"},"reference-count":47,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T00:00:00Z","timestamp":1735084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Anthracycline\u2013taxane chemotherapy is the gold standard in high-risk breast cancer (BC), despite the potential risk of congestive heart failure (CHF). A suitable alternative for anthracycline-sparing chemotherapy is through the combination of docetaxel and cyclophosphamide (TC). Methods: Through a retrospective study of stage I-III HER2-negative BC, using administrative databases, we analyzed a total of 10,634 women treated with adjuvant chemotherapy in Ontario, Canada, between 2009 and 2017. We compared TC versus standardized anthracycline\u2013taxane chemotherapies (ACT and FEC-D). We investigated the overall survival (OS), and explored the incidence of CHF, emergency department (ED) visits and febrile neutropenia. Results: With a median follow-up of 5.5 years, the 5-year analysis showed an increased OS in patients treated with TC, versus those treated with ACT, HR 0.77 (0.63\u20130.95, p = 0.015). Among ER+ BC, there was an increased OS in patients treated with ACT and FEC-D, versus those treated with TC, HR 0.70 (0.52\u20130.95, p = 0.021) and HR 0.71 (0.56\u20130.91, p = 0.007), respectively. There were no substantial differences in CHF, between TC and anthracycline-based treatments. Patients treated with TC and FEC-D had more ED visits, compared to those treated with ACT. Conclusion: Our study shows that anthracycline\u2013taxane regimens were the most commonly prescribed adjuvant chemotherapy options in HER2-negative BC. Women who received ACT had the lowest OS, likely due to their unfavorable pathology.<\/jats:p>","DOI":"10.3390\/curroncol32010006","type":"journal-article","created":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T19:29:52Z","timestamp":1735154992000},"page":"6","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline\u2013Taxane Chemotherapy in Early HER-2 Negative Breast Cancer"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7375-4346","authenticated-orcid":false,"given":"Danilo","family":"Giffoni de Mello Morais Mata","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Verspeeten Family Cancer Centre, London Health Sciences Centre, London, ON N6A 5W9, Canada"},{"name":"Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada"},{"name":"ICES Western, London, ON N6A 5W9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossanna C.","family":"Pezo","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto, ON M5S 1A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin K. W.","family":"Chan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto, ON M5S 1A1, Canada"},{"name":"Cancer Program, ICES, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Menjak","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto, ON M5S 1A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Eisen","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Juravinski Cancer Centre, Hamilton, ON L8V 1C3, Canada"},{"name":"Hamilton Health Sciences, Hamilton, ON L8V 1C3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0938-4499","authenticated-orcid":false,"given":"Maureen","family":"Trudeau","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto, ON M5S 1A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,25]]},"reference":[{"key":"ref_1","unstructured":"(2023, July 18). Female Breast Cancer\u2014Cancer Stat Facts, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.breast.2018.03.002","article-title":"Global analysis of advanced\/metastatic breast cancer: Decade report (2005\u20132015)","volume":"39","author":"Cardoso","year":"2018","journal-title":"Breast"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1200\/JCO.21.01918","article-title":"Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib with Adjuvant Endocrine Therapy for Hormone Receptor-Positive\/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS\/AFT-05\/ABCSG-42\/BIG-14-03)","volume":"40","author":"Mayer","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s40778-018-0114-z","article-title":"The Role of Steroid Hormones in Breast and Effects on Cancer Stem Cells","volume":"4","author":"Alferez","year":"2018","journal-title":"Curr. Stem. Cell Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412","article-title":"Biological subtypes of breast cancer: Prognostic and therapeutic implications","volume":"5","author":"Yersal","year":"2014","journal-title":"World J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10549-018-4801-3","article-title":"Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy","volume":"170","author":"Haque","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Korde, L.A., Somerfield, M.R., Carey, L.A., Crews, J.R., Denduluri, N., Shelley Hwang, E., Khan, S.A., Loibl, S., Morris, E.A., and Perez, A. (2021). Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J. Clin. Oncol., 39.","DOI":"10.1200\/JCO.20.03399"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1245\/s10434-020-09480-9","article-title":"The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer","volume":"28","author":"Hieken","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4956","DOI":"10.3390\/curroncol29070394","article-title":"Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer\u2014A Literature Review","volume":"29","author":"Mata","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Cortes, J., Haiderali, A., Huang, M., Pan, W., Schmid, P., Akers, K.G., Park, J.E., Frederickson, A.M., Fasching, P.A., and O\u2019Shaughnessy, J. (2023). Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: A systematic review and network meta-analysis. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11293-4"},{"key":"ref_11","unstructured":"American Cancer Society (2022, October 12). Survival Rates for Breast Cancer. Cancer Facts & Figures 2022. Atlanta, Ga: American Cancer Society; 2022. Available online: https:\/\/www.cancer.org\/cancer\/breast-cancer\/understanding-a-breast-cancer-diagnosis\/breast-cancer-survival-rates.html#references."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years","volume":"377","author":"Pan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Huo, X., Li, J., Zhao, F., Ren, D., Ahmad, R., Yuan, X., Du, F., and Zhao, J. (2021). The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: A systematic review and meta-analysis. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-07791-y"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S1470-2045(21)00288-6","article-title":"Trastuzumab for early-stage, HER2-positive breast cancer: A meta-analysis of 13 864 women in seven randomised trials","volume":"22","author":"Bradley","year":"2021","journal-title":"Lancet. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/j.clbc.2020.07.005","article-title":"Comparative Effectiveness of Adjuvant Chemotherapy in Early-Stage Breast Cancer: A Network Meta-analysis","volume":"21","author":"John","year":"2021","journal-title":"Clin. Breast Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Albain, K., Anderson, S., Arriagada, R., Barlow, W., Bergh, J., Bliss, J., Buyse, M., Cameron, D., Carrasco, E., and Clarke, M. (2012). Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet, 379.","DOI":"10.1016\/S0140-6736(11)61625-5"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials","volume":"378","author":"Abe","year":"2011","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"van Dalen, E.C., van der Pal, H.J., and Kremer, L.C. (2016). Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. Cochrane Database Syst. Rev., 3.","DOI":"10.1002\/14651858.CD005008.pub4"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kerr, A.J., Dodwell, D., McGale, P., Holt, F., Duane, F., Mannu, G., Darby, S.C., and Taylor, C.W. (2022). Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality. Cancer Treat. Rev., 105.","DOI":"10.1016\/j.ctrv.2022.102375"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijcard.2023.04.026","article-title":"Early and late onset cardiotoxicity following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors","volume":"382","author":"Serrano","year":"2023","journal-title":"Int. J. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Gent, D.G., and Dobson, R. (2023). The 2022 European Society of Cardiology Cardio-oncology Guidelines in Focus. Eur. Cardiol., 18.","DOI":"10.15420\/ecr.2022.63"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1200\/JCO.23.01428","article-title":"Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I\/USOR 07132, and NSABP B-49 [NRG Oncology])","volume":"42","author":"Geyer","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10549-018-5055-9","article-title":"Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: A systematic review and meta-analysis of randomized controlled trials","volume":"174","author":"Caparica","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1200\/JCO.2006.06.5391","article-title":"Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer","volume":"24","author":"Jones","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1200\/JCO.2016.71.4147","article-title":"Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I\/USOR 07132, and NSABP B-49 (NRG Oncology)","volume":"35","author":"Blum","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_31","unstructured":"(2022, October 18). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. STROBE Checklist for Cohort Studies. Available online: https:\/\/www.strobe-statement.org\/checklists\/."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2015.60.9271","article-title":"Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer","volume":"33","author":"Sparano","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_33","unstructured":"(2022, October 18). ICES\u2014Institute for Clinical Evaluative Sciences. Available online: https:\/\/www.ices.on.ca\/."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/jssam\/smad034","article-title":"Joint Imputation of General Data","volume":"12","author":"Robbins","year":"2023","journal-title":"J. Surv. Stat. Methodol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41416-021-01690-6","article-title":"The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer\u2014A pooled analysis of the randomised clinical trials PlanB and SUCCESS C","volume":"126","author":"Janni","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.3390\/curroncol31080335","article-title":"The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer-A Systematic Review and Meta-Analysis","volume":"31","author":"Rush","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_37","unstructured":"Audeh, W., Chmielewski-Stivers, N., Ramaswamy, H., Menicucci, A., and FLEX Investigators Group (2024., January 7\u201310). MammaPrint and BluePrint Predict Anthracycline Chemosensitivity in Patients with HR+ HER2\u2212 Early-Stage Breast Cancer Enrolled in FLEX. Proceedings of the Miami Breast Cancer Conference 2024, Miami Beach, FL, USA. Available online: https:\/\/agendia.com\/mammaprint-blueprint-predict-anthracycline-chemosensitivity-audeh-et-al-miami-breast-2024\/."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2020.08.002","article-title":"Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study","volume":"54","author":"Batra","year":"2020","journal-title":"Breast"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.2008.18.4028","article-title":"Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735","volume":"27","author":"Jones","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Khoshroo, S., Sandoughdaran, S., Sabetrasekh, P., Hajian, P., Bikdeli, P., Sabetrasekh, P., Nasrollahi, F., Mohammadi Yeganeh, L., Naeini, S.J., and Mirzaei, H.R. (2021). Dose-Dense Docetaxel versus Weekly Paclitaxel following Dose-Dense Epirubicin and Cyclophosphamide as Adjuvant Chemotherapy in Node-Positive Breast Cancer Patients: A Retrospective Cohort Analysis. Int. J. Breast Cancer, 2021.","DOI":"10.1155\/2021\/6653265"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Fountzilas, G., Dafni, U., Papadimitriou, C., Timotheadou, E., Gogas, H., Eleftheraki, A.G., Xanthakis, I., Christodoulou, C., Koutras, A., and Papandreou, C.N. (2014). Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: First report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-515"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/j.amjcard.2013.08.026","article-title":"Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity","volume":"112","author":"Lotrionte","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Grewal, K., Krzyzanowska, M.K., McLeod, S., Borgundvaag, B., and Atzema, C.L. (2020). Outcomes after emergency department use in patients with cancer receiving chemotherapy in Ontario, Canada: A population-based cohort study. CMAJ Open, 8.","DOI":"10.9778\/cmajo.20190198"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1200\/JOP.2014.000257","article-title":"Emergency room visits and hospital admission rates after curative chemotherapy for breast cancer","volume":"11","author":"Pittman","year":"2015","journal-title":"J. Oncol. Pract."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10549-015-3441-0","article-title":"Adjuvant taxane-based chemotherapy for early stage breast cancer: A real-world comparison of chemotherapy regimens in Ontario","volume":"152","author":"Torres","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/1\/6\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:00:09Z","timestamp":1760115609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/1\/6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,25]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["curroncol32010006"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32010006","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,25]]}}}